Tuesday, February 25, 2025 11:11:28 AM
There is a flaw in that argument. You are assuming 100% of the diluted shares are going to LP which we know are not.
There isn't a flaw in the argument, the hypothetical scenario that I posited simply uses easy, make believe numbers to show on an order of magnitude level how the benefit she gains from getting more shares outweighs the cost of dilution to her personally. I'm not assuming she gets 100% of the new shares, but the amount she gets easily overcomes the dilutive variable.
Also, that assumes that all shares received by Advent are all profit. Advent has overhead. From my recollection, Advent is being paid cost plus 15%.
No, it doesn't assume it's all profit. No part of what I said assumes or implies that. And no, Advent isn't being paid cost + 15. Advent is being paid FFF on milestones for development and production readiness, which is essentially the lion's share of the projects they have done to date. Advent's production contracts are, we assume based on contract language that we can see, cost+; but they have done very little work in this area so far. NWBO is paying Advent cash portions of milestone achievements that easily cover their overhead. NWBO is paying Advent stock comp on milestones as well, which for all intents and purposes are going straight to Linda as investment.
This theory doesn't make much sense.
Your counter doesn't make much sense, half of what you claim in it is demonstrably incorrect. Stop trying so hard to disprove me, and simply ponder to yourself for a second if what I say is true, does it make sense. And it makes perfect sense, I assure you.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
